SAN CARLOS, Calif.-- October 14, 2026 -- Altay Therapeutics, Inc., a biotechnology company developing novel small molecule inhibitors of transcription factors, today announced the completion of a $37 million Series...
Arthur Klausner to speak at Biotech & Life Science Global Venture Congress 2006 in New York City
News | 09. 14. 2006
